Clinical trials: Leucovorin
Colorectal Neoplasms, Neoplasm Metastasis
Study of Intravenous Aflibercept in Combination With FOLFIRI in Japanese Patients With Metastatic Colorectal Cancer
The primary objective is to determine the dose of aflibercept to be further studied in combination with irinotecan/5-fluorouracil/isovorin (FOLFIRI) in Japanese patients with metastatic colorectal cancer.
- Trial name
- NCT00921661
- Testing
- AVE0005 (aflibercept)
- Where
- Japan
- Volunteers
- 16 people
- Sponsor
- Sanofi
Metastatic Colorectal Cancer
Effect of Silymarin in Metastatic Colorectal Cancer Patients
this work is aim to assess the antitumor effect of silymarin in patients with metastatic colorectal cancer receiving chemotherapy with or without target therapy (Bevacizumab).
- Trial name
- NCT05631041
- Testing
- Silymarin
- Where
- Egypt
- Volunteers
- 64 people
- Sponsor
- Tanta University
Gastric Cancer
Bortezomib, Fluorouracil, and Leucovorin in Treating Patients With Metastatic or Unresectable Stomach Cancer
RATIONALE: Bortezomib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as fluorouracil and leucovorin, work in different ways to stop the growth of tumor…
- Trial name
- NCT00103103
- Testing
- bortezomib, fluorouracil, leucovorin calcium
- Where
- 5 sites in United States
- Sponsor
- California Cancer Consortium
Hepatocellular Carcinoma (HCC)
HAIC Combined With Sintilimab Plus Bevacizumab Biosimilar for Advanced Hepatocellular Carcinoma (TASK-03)
To evaluate HAIC combined with Sintilimab plus bevacizumab biosimilar for advanced hepatocellular carcinoma.
- Trial name
- NCT06860490
- Testing
- Sintilimab, Bevacizumab Biosimilar, HAIC
- Where
- China
- Volunteers
- 164 people
- Sponsor
- Fudan University
Adebrelimab, Hepatocellular Carcinoma
Evaluation of Effectiveness and Safety of HAIC in Combination With Adebrelimab and Bevacizumab for Potentially Resectable Hepatocellular Carcinoma
Primary liver cancer mainly consists of three different pathologic types: hepatocellular carcinoma, intrahepatic cholangiocarcinoma, and hybrid HCC-ICC, of which HCC accounts for 90%.
- Trial name
- NCT06405061
- Testing
- Adebrelimab
- Where
- 4 sites in China
- Volunteers
- 40 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Acute Myeloid Leukemia, Myelodysplastic Syndrome
Panobinostat With Fludarabine and Cytarabine for Treatment of Children With Acute Myeloid Leukemia or Myelodysplastic Syndrome
Cancer is the uncontrolled growth of human cells. The growth of normal human cells is controlled by multiple mechanisms. Panobinostat belongs to a class of chemotherapy drugs called "histone deacetylase (HDAC) inhibitors." HDAC…
- Trial name
- NCT02676323
- Testing
- Panobinostat, Fludarabine, Cytarabine
- Where
- 7 sites in United States
- Volunteers
- 19 people
- Sponsor
- St. Jude Children's Research Hospital
Hepatocellular Carcinoma (HCC), Portal Vein Tumor Thrombus
Conversion Therapy With FOLFOX-HAIC Plus Lenvatinib And Tislelizumab For Hepatocellular Carcinoma With Vp3 Portal Vein Tumor Thrombus
Patients with hepatocellular carcinoma (HCC) complicated by Vp3 portal vein tumor thrombus (PVTT) face a poor prognosis and are typically ineligible for surgical resection.
- Trial name
- CONV3RSION (NCT07483359)
- Testing
- HAIC + Tislelizumab +lenvatinib
- Where
- China
- Volunteers
- 38 people
- Sponsor
- First Hospital of China Medical University
Rectal Cancer
Total Neoadjuvant Therapy With mFOLFOX and Short-course Radiation in Resectable Rectal Cancer
This is phase 2 trial of neoadjuvant therapy and short-course radiotherapy in resectable rectal cancer.
- Trial name
- NCT04643366
- Testing
- Chemotherapy, Radiation Therapy
- Where
- 4 sites in United States
- Volunteers
- 64 people
- Sponsor
- Virginia Commonwealth University
Colorectal Cancer
Metastatic Colorectal Cancer Treated With Regorafenib and FOLFIRI
The survey is a retrospective study to evaluate the prognotic value of EGFR expression, KRAS mutations and tumor sideness in patients with metastatic colorectal cancer treated with regorafenib and FOLFIRI as a third- or…
- Trial name
- NCT03698253
- Testing
- Regorafenib, UGT1A1 genotyping (TA6/TA6), UGT1A1 genotyping (TA6/TA7)
- Where
- Taiwan
- Volunteers
- 41 people
- Sponsor
- Kaohsiung Medical University Chung-Ho Memorial Hospital
Metastatic Colorectal Cancer
IRIS Followed by mFOLFOX6 or the Reverse Sequence in Advanced Colorectal Cancer
This randomized phase III study compares safety and efficacy of two sequence arms in advanced colorectal cancer: irinotecan and S-1 (IRIS) followed by oxaliplatin containing regimen (arm A), or l-leucovorin (l-LV), 5-FU and…
- Trial name
- NCT00316745
- Testing
- Campto, Topotesin, TS-1, L-Plat
- Where
- Japan
- Volunteers
- 200 people
- Sponsor
- Hokkaido Gastrointestinal Cancer Study Group
Colorectal Cancer
Total Neoadjuvant Treatment for pMMR Locally Advanced Low Rectal Cancer: Anti-PD-1 Antibody With FOLFOXIRI and Preoperative Radiation Therapy
For locally advanced rectal cancer, the initial goal of neoadjuvant chemoradiotherapy is to reduce local recurrence, but the pathologic complete response (PCR) rate is low, and distant metastasis becomes the main treatment…
- Trial name
- NCT06099951
- Testing
- Serplulimab + FOLFOXIRI, Radiation therapy
- Volunteers
- 53 people
- Sponsor
- Sun Yat-sen University
Advanced Colorectal Cancer
LEAC-102 for Advanced Colorectal Cancer
A Phase I/IIa Dose-Escalation Study Evaluating the Safety, Tolerability and Efficacy of LEAC-102 in Combination with FOLFOX + Bevacizumab/Cetuximab in Subjects with Advanced Colorectal Cancer
- Trial name
- NCT02826837
- Testing
- LEAC-102 500mg capsule and FOLFOX + Bevacizumab/Cetuximab
- Volunteers
- 30 people
- Sponsor
- Taiwan Leader Biotech Corp.
2nd-line, 3rd-line and Greater Metastatic Pancreatic Cancer
Safety and Efficacy of Combination Listeria/GVAX Pancreas Vaccine in the Pancreatic Cancer Setting
Test the safety, immune response and efficacy of GVAX pancreas vaccine (with cyclophosphamide) and CRS-207 compared to chemotherapy or CRS-207 alone in adults with previously treated metastatic pancreatic adenocarcinoma
- Trial name
- ECLIPSE (NCT02004262)
- Testing
- GVAX Pancreas Vaccine, CRS-207, Chemotherapy
- Where
- 21 sites in United States, Canada
- Volunteers
- 303 people
- Sponsor
- Aduro Biotech, Inc.
Advanced Biliary Tract Cancer, Intrahepatic Cholangiocarcinoma
Study of Irinotecan Liposome Injection in Patients With Advanced Biliary Tract Cancer
This study is an open-label, phase II study of irinotecan liposome injection in patients with advanced biliary tract cancer. The purpose of this study is to evaluate the safety, efficacy and pharmacokinetics of irinotecan…
- Conditions
- Advanced Biliary Tract Cancer, Intrahepatic Cholangiocarcinoma, Extrahepatic Cholangiocarcinoma, Gallbladder Carcinoma
- Trial name
- NCT05009953
- Testing
- Irinotecan Liposome Injection, SG001, Fluorouracil
- Where
- China
- Volunteers
- 17 people
- Sponsor
- CSPC Ouyi Pharmaceutical Co., Ltd.
Extranodal NK/T-cell Lymphoma
BRIDGE-NK: Immunotherapy Versus Chemotherapy Induction Followed by Autologous HSCT in Advanced NKTCL
This is a randomized, open-label, prospective, multicenter phase III superiority study in patients with newly diagnosed stage IV extranodal NK/T-cell lymphoma.
- Trial name
- BRIDGE-NK (NCT07678229)
- Testing
- GELAD regimen, MEDA regimen, LEAP regimen
- Where
- China
- Volunteers
- 150 people
- Sponsor
- Rong Tao
Malignant Biliary Tract Tumors
A Prospective, Open-Label, Randomized Controlled Clinical Study Comparing Hepatic Arterial Infusion Chemotherapy (HAIC) With Capecitabine as Adjuvant Therapy After Radical Surgery for Malignant Biliary Tract Tumors
3. Study Design 3.1.1 Study Site and Overall Population Overview This study is a prospective, open-label, randomized controlled clinical trial designed to observe and evaluate the efficacy and safety of hepatic arterial infusion…
- Trial name
- NCT07790445
- Testing
- Oxaliplatin + 5-Fluorouracil/Leucovorin, Capecitabine
- Where
- China
- Volunteers
- 90 people
- Sponsor
- Zhai Wenlong
Ductal Adenocarcinoma of the Pancreas
Trial to Investigate Intensified Neoadjuvant Chemotherapy in Locally Advanced Pancreatic Cancer
The aim ot the study is to investigate the efficacy and safety of two new intensified chemotherapy regimens (gemcitabine (Gem)/nab- paclitaxel (PAC), FOLFIRINOX) as neoadjuvant chemotherapy protocol in locally advanced…
- Trial name
- NEOLAP (NCT02125136)
- Testing
- Gem/nab-Pac, FOLFIFINOX
- Where
- Germany
- Volunteers
- 168 people
- Sponsor
- AIO-Studien-gGmbH
Metastatic Pancreatic Cancer
Efficacy of ABI-007 Plus Gemcitabine or sLV5FU2 as First-line Therapy in Patients With Metastatic Pancreatic Cancer
To evaluate the combination of ABI-007 with gemcitabine or with LV5FU2.
- Trial name
- AFUGEM (NCT01964534)
- Testing
- ABI-007, Gemcitabine, simplified LV5FU2
- Where
- 15 sites in France
- Volunteers
- 114 people
- Sponsor
- GERCOR - Multidisciplinary Oncology Cooperative Group
Pancreatic Adenocarcinoma
Alternative Neoadjuvant Chemotherapy in Resectable and Borderline Resectable Pancreatic Cancer
Using alternative neoadjuvant gemcitabine-nab-paclitaxel and nal-IRI with 5-Fluorouracil (5FU) and folinic acid (Leucovorin) regimens of localized cancer, we hope to ensure exposure of the cancer to a broader array of potentially…
- Trial name
- NCT03703063
- Testing
- Gemcitabine, nab paclitaxel, Onivyde
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Benaroya Research Institute
Advanced Esophageal Carcinoma
FOLFIRI as Second Line Chemotherapy for Metastatic Esophageal Carcinoma
This phase Ⅱ study was designed to evaluate the efficacy and safety of FOLFIRI as second-line treatment for metastatic esophageal carcinoma.
- Trial name
- NCT02023593
- Testing
- FOLFIRI
- Where
- China
- Volunteers
- 35 people
- Sponsor
- Yuhong Li
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.